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lateral LV and RV free walls (RVFW). 29 age-matched healthy subjects served as Con-
trols.
Results: S/SR values were similar in Tx and Controls except in the septum and RVFW.
Unlike the normal base-apex myocardial velocity gradient, S/SR were homogenous
throughout all walls for Tx and Controls. Because of this homogeneity, values were aver-
aged for every wall. 
*p<0.005
Conclusion: SRI is a robust and reproducible technique for the quantification of regional
myocardial function in Tx pts. Although global systolic function indices were normal, long
axis peak systolic S/SR were reduced in the septum and RVFW post Tx. These findings
must be taken into account when using SRI to detect further abnormalities in Tx hearts.
1089-119 Pentoxifylline Protects Allogenic Transplanted Hearts
Nour Eddine El Mokhtari, Alexander Reinecke, Bettina Dresske, Markus Lins, Dietmar 
Krueger, Andreas Tiroke, Stefan Hirt, Rudiger Simon, University of Kiel, Kiel, Germany
Background:
We studied whether pentoxifylline, an important modulator of proinflammatory and
proapoptotic cytokines, attenuates allograft rejection in an experimental model of hetero-
topic heart transplantation.
Methods: 
In age matched male rats, different transplantational settings were performed. Hearts
from Fisher 344 rats were abdominally transplanted to Wistar Kyoto rats (WKY) receiving
daily intraperitoneally injections of pentoxifylline (25mg/kg BW) or vehicle, respectively.
Additionally, syngenic transplantations from WKY to vehicle treated WKY served as con-
trols.
For investigating allograft survival, heartbeats were daily controlled by palpation (n=15 for
each setting) up to 150 days after transplantation.
For investigating rejection and apoptotic cell death in the allografts, all specimens were
graded according to the International Society for Heart and Lung Transplantation (ISHLT)
Criteria and the number of apoptotic cells per left ventricular cross-section derived from
TUNEL assays performed at day 3, 6, and 15 after transplantation (n=6 for each time
point and setting).
Results:
Comparted to vehicle treatment (21±5 days), pentoxifylline treatment significantly
(p<0.01) improved mean allograft survival time (70± 24 days), whereas none of the syn-
genically transplanted WKY hearts were rejected throughout the protocol. Accordingly,
pentoxiffylline treatment showed a highly significant (p<0.001) reduction of the time-
dependent increase in apoptotic cell death (up to a twenty fold reduction at day 15).
Conclusions:
This study showed for the first time that pentoxifylline treatment could be an effective tool
for preventing rejection after heart transplantation. This finding could be of great clinical
importance.
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821-1 Should Beta-Blockers Be Used Before Angiotensin 
Converting Enzyme Inhibitors in Patients With Chronic 
Heart Failure? Meta-Analysis of the Prognostic Benefit 
Conferred by Beta-Blockers in Patients Not Receiving 
ACE Inhibitors
Henry Krum, Steven Haas, Jalal Ghali, Edward Gilbert, Phillipe Lechat, Mary-Ann Lukas, 
Milton Packer, Ellen Roecker, Patricia Verkenne, Hans Wedel, John Wikstrand, The Beta-
Blockers in Heart Failure Collaborative Group, Monash University, NHMRC CCRE in 
Therapeutics, Melbourne Victoria, Australia
Background: Beta-blockers (BBs) confer significant prognostic benefit in patients (pts)
with chronic heart failure (CHF), however major trials have thus far studied BBs mainly in
addition to ACE inhibitors (ACEi) as background therapy. The magnitude of the prognos-
tic benefit of BB’s in the absence of ACEi has not as yet been determined.
Methods: We performed a meta-analysis of all available, large (n>500), placebo (PBO)-
controlled studies of BBs in patients with CHF. Trials were identified via Medline literature
searches, from meeting abstracts and contact with study organisations. Results were
pooled using the Mantel-Haenszel method.
Results: The impact of beta-blocker therapy on all-cause mortality in CHF, in the
absence (4.3%) and presence (95.7%) of ACEi therapy at baseline, is shown in the Table.
The overall relative risk (RR) of 0.67 (0.43-1.04) for BBs in the absence of ACEi therapy
at baseline appears to exceed that for ACEi studied vs PBO in the pre-BB era of CHF
(0.77 [0.67 - 0.88]). 
Conclusions: The magnitude of the prognostic benefit conferred by BBs in the absence
of ACEi exceeds those of ACEi in CHF. These data therefore support the early introduc-
tion of BBs to pts with CHF. Prospective studies directly comparing BBs and ACEi as first-
line agents are required to definitively address this issue.
*Garg, Yusuf. JAMA 1995;273:1450-1456.
2:15 p.m.
821-2 Characteristics of Heart Failure Patients in Clinical 
Practice: How Do They Relate to Ejection Fraction?
Barry M. Massie, Jeanenne J. Nelson, Mary Ann Lukas, Sandra R. Lottes, Barry 
Greenberg, Michael B. Fowler, Edward M. Gilbert, William T. Abraham, Joseph A. 
Franciosa, and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background and methods: Clinical trials usually categorize heart failure (HF) patients
dichotomously by left ventricular ejection fraction (EF). In the community setting patient
characteristics and physician practices vary across the entire EF range. From the Coreg
Heart Failure Registry (COHERE) of 4,280 patients initiating carvedilol for HF in the com-
munity we related baseline EF quartiles to patient characteristics, treatments, and out-
comes.
Results: Findings are in the table. Age, proportions of women, hypertensives or diabet-
ics, and baseline BP all increased with increasing EF. Patients with lower EF had higher
NYHA class and more HF hospitalizations in the prior year. ACE inhibitor use declined
with increasing EF as did achievement of recommended maximal doses of carvedilol,
and total daily dose was lowest in EF >40% group (26 ± 21 mg) and highest in the EF
<20% group (33 ± 23 mg). Symptoms improved more often in the lower EF groups. Hos-
pitalizations for HF were reduced during follow-up vs the prior year in all groups, with a
greater decline in lower EF groups. Though mortality at 1 yr was highest in the lower EF
quartiles, apparent statistically significant differences became not significant when
adjusted for age, gender, co-morbidities and other baseline characteristics. 
Conclusion: These observations indicate that the characteristics and treatment of HF 
patients initiating beta-blockers in the community vary in a graduated, not dichotomous 
manner, across the range of EF.
Tx Controls
Walls SR (1/s) S (%) SR (1/s) S (%)
septum
lateral
anterior
inferior
RVFW
1,3±0,4*
1,9±0,9
1,8±0,7
1,6±0,6
2,1±1,7*
16±7*
18±8
18±7
19±7
21±9*
1,8±0.5
1,8±0.8
1,8±0.9
1,7±0.5
3,3±1.3
23±6
18±6
19±5
21±4
42±13
No ACEi ACEi
PBO BB RR (95% CI) PBO BB RR (95% CI)
Events n Events n Events n Events n
CIBIS I 4 29 2 34 0.43 (0.08 – 
2.16)
63 292 51 286 0.83 (0.59 – 1.15)
CIBIS II 8 46 12 54 1.28 (0.57 – 
2.85)
220 1274 144 1273 0.66 (0.54 – 0.80)
COPERNICUS 11 32 6 33 0.53 (0.22 – 
1.26)
179 1101 124 1123 0.68 (0.55 – 0.84)
MERIT-HF 12 76 9 92 0.62 (0.28 – 
1.39)
205 1925 136 1898 0.67 (0.55 – 0.83)
US Carvedilol 2 19 0 41 0.10 (0.00 – 
1.89)
29 379 22 655 0.44 (0.26 – 0.75)
TOTAL 37 202 29 254 0.67 (0.43 – 
1.04)
696 4971 477 5235 0.67 (0.60 – 0.75)
Patient Characteristic/outcome Quartile 1
EF_ 20% 
(n=1039)
Quartile 
2
EF 21-
30%
(n=1304)
Quartile 3
EF 31-
40%
(n=1107)
Quartile 
4
EF > 
40%
(n=700)
p value (for the 
distribution)
LVEF (%) 17±3 27±3 36±3 52±9 <0.001
Age (yr) 65±13 66±13 67±12 68±13 <0.001
Women 30% 33% 32% 46% <0.001
Prior myocardial infarction 38% 45% 45% 34% <0.001
History of hypertension 54% 54% 60% 66% <0.001
Diabetes 29% 32% 32% 35% P=0.035
NYHA class III or IV 49% 41% 32% 28% <0.001
Systolic BP (mm Hg) 122+20 128+20 131+20 135+21 <0.001
On ACE inhibitor 80% 78% 75% 66% <0.001
On diuretic 87% 76% 71% 70% <0.001
On digoxin 73% 63% 50% 39% <0.001
Carvedilol titrated to _25 mg 
BID
49% 47% 47% 33% <0.001
NYHA class improved 36% 32% 26% 22% <0.001
NYHA class worsened 10% 11% 11% 8% P=0.28
HF hospitalization, prior yr 40% 28% 23% 19% <0.001
HF hospitalization, during 1 yr 
follow-up
13%* 12%* 10%* 11%* P=0.25
12-month mortality (unadjusted) 11.0% 9.0% 6.6% 6.8% <0.01
* p <0.001 vs prior yr
